Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$12.21B
Positions
95
New
5
Increased
13
Decreased
20
Sold Out
9
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $12.21B across 95 positions in their Q4 2018 SEC 13F filing (period ending 2018-12-31). The top 10 positions account for 86.1% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $2.89B | 23.68% | - |
| 2 | INCYIncyte Corporation | $2.18B | 17.83% | +0.0% |
| 3 | ONCBeiGene, Ltd. | $1.68B | 13.74% | - |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $833.00M | 6.82% | - |
| 5 | GHDXGenomic Health, Inc. | $756.43M | 6.19% | -14.8% |
| 6 | BMRNBioMarin Pharmaceutical Inc. | $646.23M | 5.29% | +0.1% |
| 7 | ACADACADIA Pharmaceuticals Inc. | $642.17M | 5.26% | +39.6% |
| 8 | Amarin Corporation plc | $579.69M | 4.75% | +25.0% |
| 9 | ASNDUSDAscendis Pharma A/S | $177.76M | 1.46% | - |
| 10 | MDGLMadrigal Pharmaceuticals, Inc. | $131.80M | 1.08% | - |
| Stock | Value | Shares |
|---|---|---|
| KODKodiak Sciences Inc. | $64.93M | 9,145,115 |
| TPIVDEURMarker Therapeutics, Inc. | $8.32M | 1,500,000 |
| SRRAEURSierra Oncology, Inc. | $2.64M | 2,000,000 |
| ORTXUSDOrchard Therapeutics plc | $1.97M | 125,000 |
| VSAREURAravive, Inc. | $1.42M | 404,384 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.